Efficiency of Akkermansia muciniphila in type 2 diabetes and obesity

Farzaneh Mohammadzadeh Rostami, Saman Shalibeik, Bahram Nasr Esfahani

Abstract


Akkermansia muciniphila is an anaerobic species of gut microbiome that has been proposed as a new functional microbiota with probiotic properties. Recent research has shown the amazing abilities of probiotic bacteria, A. muciniphila, which resides in most people's intestines. These bacteria affect the body if it increases or decreases abdominal fat. The presence of A. muciniphila has opened new ways for the use of this plentiful intestinal symbiont in next-generation therapeutic products, as well as targeting microbiota dynamics. A. muciniphila is particularly effective in increasing mucosal thickness and enhancing bowel barrier function. As a result, host metabolic markers improve. The host functions that are disrupted in various diseases with a particular focus on metabolic disorders in animals and humans. A specific protein in the outer membrane of A. muciniphila called Amuc-110 could in the future be a strong candidate for drug production. As a result, we suggest that microbes and our microbiology or gut microbiome knowledge could be a new source for future treatments. The objectives of this review are to summarize the data available on the distribution of A. muciniphila gut in health and disease, to provide insights into the environment and its role in the creation of microbial networks at the mucosal interface, as well as to discuss recent research on its role in regulation.

Keywords


Akkermansia muciniphila; Type 2 diabetes; Obesity; Prebiotics

References


Euzéby JP. List of Bacterial Names with Standing in Nomenclature: a folder available on the Internet. Int J Syst Evol Microbiol. 1997;47(2):590-2.

Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65(3):426-36.

Gómez-Gallego C, Pohl S, Salminen S, De Vos W, Kneifel W. Akkermansia muciniphila: a novel functional microbe with probiotic properties. Benef Microbes. 2016;7(4):571-84.

Zhou K. Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies. J Funct Foods. 2017;33:194-201.

Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci. 2013;110(22):9066-71.

Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-103.

Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107-13.

Belzer C, De Vos WM, Cani PD. Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status. Google Patents; 2018.

Naito Y, Uchiyama K, Takagi T. A next-generation beneficial microbe: Akkermansia muciniphila. J Clin Biochem Nutr. 2018;63(1):33-5.

Roubalová R, Procházková P, Papežová H, Smitka K, Bilej M, Tlaskalová-Hogenová H. Anorexia nervosa: Gut microbiota-immune-brain interactions. Clinical Nutrition. 2020;39(3):676-84.

Seebeck T, Chen F, Davis GD. Engineered cas9 systems for eukaryotic genome modification. Google Patents; 2019.

Cheng P, Yao L, Chen X, Su X, Su X, Huang Q, et al. An inflammatory memory and angiogenic self-assembling nanofiber hydrogel scaffold seeded with Akkermansia muciniphila to accelerate the healing of diabetic ischemic ulcers. RSC Adv. 2018;8(31):17357-64.

Remely M, Hippe B, Zanner J, Aumueller E, Brath H, G Haslberger A. Gut microbiota of obese, type 2 diabetic individuals is enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after weight loss. Endocr Metab Immune Disord Drug Targets. 2016;16(2):99-106.

Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol. 2017;8:1765.

Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401-12.

Roberfroid M. Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr. 1998;80(S2):S197-S202.

Rostami FM, Mousavi H, Mousavi MRN, Shahsafi M. Efficacy of probiotics in prevention and treatment of infectious diseases. Clin Microbiol Newsl. 2018;40(12):97-103.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72.

Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54(5):1469-76.

Ouwehand AC, Derrien M, de Vos W, Tiihonen K, Rautonen N. Prebiotics and other microbial substrates for gut functionality. Curr Opin Biotechnol. 2005;16(2):212-7.

Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl Environ Microbiol. 2008;74(5):1646-8.

Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 2011;60(11):2775-86.

Everard A, Lazarevic V, Gaïa N, Johansson M, Ståhlman M, Backhed F, et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J. 2014;8(10):2116-30.

Yan M, Song M-M, Bai R-X, Cheng S, Yan W-M. Effect of Roux-en-Y gastric bypass surgery on intestinal Akkermansia muciniphila. World J Gastrointest Surg. 2016;8(4):301.

Cani PD. Microbiota and metabolites in metabolic diseases. Nat Rev Endocrinol. 2019;15(2):69-70.

Macchione I, Lopetuso L, Ianiro G, Napoli M, Gibiino G, Rizzatti G, et al. Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders. Eur Rev Med Pharmacol Sci. 2019;23(18):8075-83.

Zhang L, Carmody RN, Kalariya HM, Duran RM, Moskal K, Poulev A, et al. Grape proanthocyanidin-induced intestinal bloom of Akkermansia muciniphila is dependent on its baseline abundance and precedes activation of host genes related to metabolic health. J Nutr Biochem. 2018;56:142-51.

Anhê FF, Pilon G, Roy D, Desjardins Y, Levy E, Marette A. Triggering Akkermansia with dietary polyphenols: A new weapon to combat the metabolic syndrome? Gut Microbes. 2016;7(2):146-53.

Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3(4):279-88.

Ganesh BP, Klopfleisch R, Loh G, Blaut M. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice. PloS One. 2013;8(9):e74963.

Hutkins RW, Krumbeck JA, Bindels LB, Cani PD, Fahey Jr G, Goh YJ, et al. Prebiotics: why definitions matter. Curr Opin Biotechnol. 2016;37:1-7.

Kaplan M, Mutlu EA, Benson M, Fields JZ, Banan A, Keshavarzian A. Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders. Complement Ther Med. 2007;15(3):207-16.

Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017; 14(2):79-87.

Gülden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes. Clin Immunol. 2015; 159(2):143-53.

Schneeberger M, Everard A, Gómez-Valadés AG, Matamoros S, Ramírez S, Delzenne NM, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep. 2015;5:16643.

Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Front Microbiol. 2020; 11:219.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.